Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial

Autor: Botsen, Damien, Chabaud, Sylvie, Perrier, Hervé, Ammarguellat, Hanifa, Jestin-Le-Tallec, Véronique, Olesinski, Jonathan, Toullec, Clémence, Aparicio, Thomas, Ben Abdelghani, Meher, Borg, Christophe, Bouche, Olivier, Coutzac, Clélia, Devaud, Hervé, Di Fiore, Frédéric, Dubreuil, Olivier, Evesque, Ludovic, Huguenin, Bruno, Muller, Marie, Poureau, Pierre-Guillaume, Oularue, Emilie, Tougeron, David, Zaanan, Aziz, Ammari, Samy, De Sousa Carvalho, Nicolas, Decazes, Pierre, De La Fouchardiere, Christelle
Zdroj: In Digestive and Liver Disease August 2024 56(8):1281-1287
Databáze: ScienceDirect
Externí odkaz: